Aranjuez
Ercros' pharmaceuticals division's headquarters and production centre
Over 75 years of expertise serving the pharmaceutical industry
The Aranjuez plant (Madrid) has a long-standing history in the pharmaceutical industry. Since its beginnings in penicillin production, it has developed extensive expertise in the manufacture of active pharmaceutical ingredients (APIs), particularly antibiotics, using fermentation and chemical synthesis technologies.
Today, the plant combines the production of generic APIs with a growing focus on contract development and manufacturing (CDMO), offering tailored solutions to the pharmaceutical industry.
The plant has three multipurpose synthesis and fermentation production units, a facility for the production and blending of sterile products, and a laboratory and R&D centre. These facilities, together with its technical and regulatory expertise, enable the plant to undertake projects involving process development, technology transfer, industrial scale-up, and the manufacture of active pharmaceutical ingredients and pharmaceutical intermediates.
Ercros is the world's second-largest producer of fusidic acid and the third-largest producer of fosfomycin. Its product portfolio also includes macrolide antibiotics, antiulcer agents, antihypertensives and antifungals.
With a workforce of 230 employees and an annual production capacity of approximately 430,000 kg, the Aranjuez plant exports 95% of its output to international markets, primarily the European Union, the United States, the Middle East and North Africa.
In figures
The key figures of the Aranjuez factory
Workforce
Annual production capacity
Exports
Company manufacturing antibiotics in Spain
Multimedia
Download graphic resources of the Aranjuez factory
A bit of history

Compañía Española de Penicilicilina y Antibióticos (Cepa) in collaboration with the American company Merck & Co. Inc. wins a tender called by the Spanish government to develop a national antibiotics industry and becomes the first company to manufacture penicillin in Spain.

Inauguration of the Aranjuez factory, under the ownership of Cepa, with the most advanced equipment and processes. Its production capacity is 1.5 million vials of crystallised sodium penicillin per month.

After several expansions of its facilities, the initial production of penicillin is doubled to meet the needs of the Spanish market.

Cepa, together with Merck, is developing a new antibiotic, fosfomycin, a market in which the Aranjuez factory will be one of the world leaders.

Start of industrial-scale production of fosfomycin and, two years later, of a new antibiotic, erythromycin.

Cepa is acquired by Unión Explosivos Río Tinto, S.A. (ERT), the predecessor of Ercros.

As a result of the merger of ERT and S.A. Cros to form Ercros, Cepa is split into two companies. One of them, Fermentaciones y Síntesis Españolas, S.A. (Fyse), retains the API manufacturing and the Aranjuez factory facilities and joins Ercros.

Industrial-scale production of the erythromycin derivatives, azithromycin and clarithromycin, begins.

Commercialisation of fusidic acid begins.

A new multi-purpose plant is commissioned to manufacture synthesis products. This considerably increases the centre's production volume.

Industrial production of fosfomycin trometamol begins.

Inauguration of a sterile product mixing and packaging plant.

Expansion of the fermentation capacity and the synthetic products plant. A new sterile products plant is commissioned to replace the existing one.

Celebration of the 75th anniversary and inauguration of the new extraction plant, with an annual production capacity of 150,000 kilos.
Photo gallery of the factory's 75th anniversary
Certificates of the Aranjuez factory
The distinctive marks that endorse this factory's commitment to sustainability.
Contact the factory
If you would like to visit or contact us, you can start here.
Paseo del Deleite, s/n
28300 Aranjuez (Madrid)
Tel: +34 918 090 340
Email: aranjuez@ercros.es




























